Perfuse Therapeutics brings Bayer an eye drug administered via an implant that controls the release of the therapy. This program is in mid-stage clinical development for glaucoma and diabetic retinopathy.
Roon is a new physician-only social network. The platform — founded by a neurosurgeon and two former Pinterest executives — aims to surface the “collective wisdom” of doctors that currently lives in informal exchanges and fragmented online communities.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
April has seen a slew of executive hires, promotions and layoffs across the healthcare industry. For instance, Aledade, Humana and Zimmer Biomet named new executives. There were also layoffs at organizations including Baylor Scott & White Health Plan, Novo Nordisk and UnityPoint Health.
Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis.
Nvidia and Hoppr are betting that healthcare AI will scale not through standalone applications, but through a new infrastructure layer that lets providers develop and deploy their own imaging models.
Midstream Health is taking a bit of a different approach to healthcare AI by focusing on reducing hospitals’ costs rather than boosting their revenue. The startup uses AI to identify savings opportunities across fragmented spending data, which helps health systems like Mount Sinai and CommonSpirit quickly improve their purchasing decisions.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.
Telehealth clinic Hone Health partnered with imaging company BodySpec to give its patients access to DEXA body composition scans. The partnership seeks to help providers and patients on GLP-1s distinguish fat loss from muscle loss and better evaluate how these drugs are affecting the body.
The AI Health Fund launched Treehub, a new residency program designed to back and build healthcare AI startups at the earliest stages, often before companies are even formed. It is supported by prominent figures in the Silicon Valley venture capital world, including Tim Draper and Anne Wojcicki.
Tortugas Neurosciences’ two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led by veterans of Sage Therapeutics, a neuroscience biotech that was acquired last year.
How to turn analytics into actual policy outcomes.
Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly’s acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines.
CMS is rolling out its health tech ecosystem initiative with a new Medicare app library that functions like a healthcare “App Store,” aiming to make patient data more portable and accessible across vetted digital health apps.
The fatty liver disease MASH is one of the metabolic disorders that Nula Therapeutics is pursuing. The startup’s small molecules are intended to restore the integrity of the nuclear envelope, a cellular membrane whose dysfunction can contribute to metabolic disease.
Innovaccer is committing $250 million to expand its AI agent platform, which automates workflows across areas like prior authorization, revenue cycle management and population health. The move comes amid an ongoing debate over whether administrative AI tools can ultimately reduce costs for providers.
Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance.